Apex Biotechnology Corp. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was TWD 605.48 million compared to TWD 509.47 million a year ago. Net income was TWD 64 million compared to TWD 64.04 million a year ago. Basic earnings per share from continuing operations was TWD 0.64 compared to TWD 0.64 a year ago. Diluted earnings per share from continuing operations was TWD 0.64 compared to TWD 0.64 a year ago.
For the nine months, sales was TWD 1,735.54 million compared to TWD 1,570.34 million a year ago. Net income was TWD 138.65 million compared to TWD 120.67 million a year ago. Basic earnings per share from continuing operations was TWD 1.39 compared to TWD 1.21 a year ago. Diluted earnings per share from continuing operations was TWD 1.38 compared to TWD 1.14 a year ago.